Endo (OTCPK:NDOI) - Stock Price, News & Analysis

NDOI Stock Overview

A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.

About the company

NDOI fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	3/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (0.5x) is below the US market (18.3x)

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

High level of non-cash earnings

Endo Inc. Competitors

Ligand Pharmaceuticals

NasdaqGM:LGND

US$1.8b

Innoviva

NasdaqGS:INVA

US$1.2b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.3b

Prestige Consumer Healthcare

NYSE:PBH

US$3.5b

Price History & Performance

Summary of all time highs, changes and price drops for Endo
Historical stock prices
Current Share Price	US$25.05
52 Week High	US$29.75
52 Week Low	US$24.46
Beta	0
11 Month Change	-7.22%
3 Month Change	-11.33%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-11.33%

Recent updates

Shareholder Returns

	NDOI	US Pharmaceuticals	US Market
7D	-3.7%	-2.6%	0.7%
1Y	n/a	20.9%	32.3%

Return vs Industry: Insufficient data to determine how NDOI performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NDOI performed against the US Market.

Price Volatility

Is NDOI's price volatile compared to industry and market?
NDOI volatility
NDOI Average Weekly Movement	7.7%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

Stable Share Price: NDOI has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NDOI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	2,931	Scott Hirsch	www.endo.com

Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. It operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment offers products for the treatment of conditions in urology, orthopedics, and endocrinology.

Endo Inc. Fundamentals Summary

How do Endo's earnings and revenue compare to its market cap?
NDOI fundamental statistics
Market cap	US$1.91b
Earnings (TTM)	US$3.57b
Revenue (TTM)	US$1.82b

0.5x

P/E Ratio

1.1x

P/S Ratio

Is NDOI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NDOI income statement (TTM)
Revenue	US$1.82b
Cost of Revenue	US$944.81m
Gross Profit	US$870.73m
Other Expenses	-US$2.70b
Earnings	US$3.57b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	46.76
Gross Margin	47.96%
Net Profit Margin	196.79%
Debt/Equity Ratio	133.0%

How did NDOI perform over the long term?

See historical performance and comparison

Endo OTCPK:NDOI Stock Report